Dean Capital Investments Management LLC Has $1.03 Million Stock Holdings in Novo Nordisk A/S (NYSE:NVO)

Dean Capital Investments Management LLC grew its stake in shares of Novo Nordisk A/S (NYSE:NVO) by 15.7% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 19,990 shares of the company’s stock after acquiring an additional 2,714 shares during the quarter. Novo Nordisk A/S comprises approximately 0.6% of Dean Capital Investments Management LLC’s portfolio, making the stock its 10th biggest position. Dean Capital Investments Management LLC’s holdings in Novo Nordisk A/S were worth $1,033,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors also recently modified their holdings of the company. Carroll Financial Associates Inc. increased its holdings in Novo Nordisk A/S by 3.2% in the 2nd quarter. Carroll Financial Associates Inc. now owns 11,805 shares of the company’s stock worth $602,000 after buying an additional 369 shares in the last quarter. Capital Insight Partners LLC grew its stake in shares of Novo Nordisk A/S by 1.7% during the 2nd quarter. Capital Insight Partners LLC now owns 17,049 shares of the company’s stock valued at $870,000 after purchasing an additional 285 shares during the period. Crossmark Global Holdings Inc. grew its stake in shares of Novo Nordisk A/S by 1.9% during the 2nd quarter. Crossmark Global Holdings Inc. now owns 81,009 shares of the company’s stock valued at $4,135,000 after purchasing an additional 1,509 shares during the period. Arlington Partners LLC grew its stake in shares of Novo Nordisk A/S by 870.8% during the 2nd quarter. Arlington Partners LLC now owns 48,150 shares of the company’s stock valued at $2,458,000 after purchasing an additional 43,190 shares during the period. Finally, Valeo Financial Advisors LLC grew its stake in shares of Novo Nordisk A/S by 510.7% during the 2nd quarter. Valeo Financial Advisors LLC now owns 629 shares of the company’s stock valued at $32,000 after purchasing an additional 526 shares during the period. Hedge funds and other institutional investors own 7.35% of the company’s stock.

Shares of NVO stock traded down $0.04 during trading hours on Tuesday, reaching $57.25. 17,330 shares of the company traded hands, compared to its average volume of 1,256,669. Novo Nordisk A/S has a 12-month low of $43.12 and a 12-month high of $57.93. The company has a debt-to-equity ratio of 0.06, a current ratio of 1.00 and a quick ratio of 0.73. The company has a market cap of $135.66 billion, a P/E ratio of 22.75, a P/E/G ratio of 2.33 and a beta of 0.61. The firm has a 50-day moving average price of $53.35 and a 200 day moving average price of $50.70.

Novo Nordisk A/S (NYSE:NVO) last posted its quarterly earnings data on Friday, November 1st. The company reported $0.64 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.62 by $0.02. Novo Nordisk A/S had a return on equity of 75.48% and a net margin of 32.44%. The firm had revenue of $4.51 billion for the quarter, compared to analysts’ expectations of $4.55 billion. Sell-side analysts predict that Novo Nordisk A/S will post 2.45 EPS for the current year.

A number of equities research analysts have issued reports on NVO shares. Bank of America boosted their price target on Novo Nordisk A/S from $355.00 to $400.00 and gave the company a “neutral” rating in a research note on Friday, September 13th. ValuEngine upgraded Novo Nordisk A/S from a “sell” rating to a “hold” rating in a research note on Friday, November 1st. Citigroup upgraded Novo Nordisk A/S from a “neutral” rating to a “buy” rating in a research note on Tuesday, September 17th. Pareto Securities upgraded Novo Nordisk A/S from a “hold” rating to a “buy” rating in a research note on Monday, August 5th. Finally, Zacks Investment Research upgraded Novo Nordisk A/S from a “sell” rating to a “hold” rating and set a $50.00 price target for the company in a research note on Monday, July 15th. Two analysts have rated the stock with a sell rating, eight have assigned a hold rating and six have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and an average price target of $159.65.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, a healthcare company, engages in the development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes Care and Obesity, and Biopharmaceuticals. The Diabetes Care and Obesity segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral anti-diabetic products, obesity, and other chronic diseases.

Featured Story: Mutual Funds

Institutional Ownership by Quarter for Novo Nordisk A/S (NYSE:NVO)

Receive News & Ratings for Novo Nordisk A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novo Nordisk A/S and related companies with MarketBeat.com's FREE daily email newsletter.